Models:
Joseph Gordon
joseph-gordon/
ClinicalTrialsElig
0
Downloads: 1
[c09aa8]: / clusters / 9knumclustersv2 / clust_1386.txt

Download this file

24 lines (23 with data), 7.2 kB 

 1
 2
 3
 4
 5
 6
 7
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
Patients with  or fewer brain metastases that are less than  cm in diameter and asymptomatic are eligible; lesions that have been treated with stereotactic radiosurgery must be clinically stable for  month after treatment for the patient to be eligible; patients with surgically resected brain metastases are eligible

Patients with  or fewer brain metastases that are less than  cm in diameter and asymptomatic are eligible; lesions that have been treated with stereotactic radiosurgery must be clinically stable for  month after treatment for the patient to be eligible; patients with surgically resected brain metastases are eligible

Patients with  or fewer brain metastases that are less than  cm in diameter and asymptomatic are eligible; lesions that have been treated with stereotactic radiosurgery must be clinically stable for  month after treatment for the patient to be eligible; patients with surgically resected brain metastases are eligible

Patients with  or fewer brain metastases that are less than  cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for  month after treatment for the patient to be eligible. Patients with surgically resected brain metastases are eligible.

Patients with  or fewer brain metastases that are less than  centimeter (cm) in diameter and asymptomatic are eligible; lesions that have been treated with stereotactic radiosurgery must be clinically stable for one month after treatment for the patient to be eligible; patients with surgically resected brain metastases are eligible

For cohorts -, patients with  or fewer brain metastases that are less than  cm in diameter and asymptomatic are eligible; lesions that have been treated with stereotactic radiosurgery must be clinically stable for  month after treatment for the patient to be eligible; patients with surgically resected brain metastases are eligible

Patients with  or fewer brain metastases that are less than  cm in diameter and asymptomatic are eligible; lesions that have been treated with stereotactic radiosurgery must be clinically stable for one month after treatment for the patient to be eligible; patients with surgically resected brain metastases are eligible

Patients with  or fewer brain metastases that are less than  cm in diameter and asymptomatic are eligible; lesions that have been treated with stereotactic radiosurgery must be clinically stable for  month after treatment for the patient to be eligible; patients with surgically resected brain metastases are eligible

Patients with three or fewer brain metastases that have been treated with surgery or stereotactic radiosurgery are eligible; lesions that have been treated with stereotactic radiosurgery must be clinically stable for one month before protocol treatment; patients with surgically resected brain metastases are eligible

Patients with  or fewer brain metastases that are less than  cm in diameter and asymptomatic are eligible; lesions >  cm that have been treated with stereotactic radiosurgery must be clinically stable for  month after treatment for the patient to be eligible; patients with surgically resected brain metastases are eligible

Patients with  or fewer brain metastases that are less than  cm in diameter and asymptomatic are eligible; lesions that have been treated with stereotactic radiosurgery must be clinically stable for  month after treatment for the patient to be eligible; patients with surgically resected brain metastases are eligible

Patients with  or fewer brain metastases that are less than  cm in diameter and asymptomatic are eligible; lesions that have been treated with stereotactic radiosurgery must be clinically stable for  month after treatment for the patient to be eligible; patients with surgically resected brain metastases are eligible

Patients with  or fewer brain metastases that are less than  cm in diameter and asymptomatic are eligible; lesions that have been treated with stereotactic radiosurgery must be clinically stable for  month after treatment for the patient to be eligible; patients with surgically resected brain metastases are eligible

Patients with  or fewer brain metastases that are less than  cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for  month after treatment for the patient to be eligible. Patients with surgically resected brain metastases are eligible

Patients with  or fewer brain metastases that are less than  cm in diameter and asymptomatic are eligible; lesions that have been treated with stereotactic radiosurgery must be clinically stable for  month after treatment for the patient to be eligible; patients with surgically resected brain metastases are eligible

Patients with  or fewer brain metastases that are less than  cm in diameter and asymptomatic are eligible; lesions that have been treated with stereotactic radiosurgery must be clinically stable for  month after treatment for the patient to be eligible; patients with surgically resected brain metastases are eligible

Patients with  or fewer brain metastases that are less than  cm in diameter and asymptomatic are eligible; lesions that have been treated with stereotactic radiosurgery must be clinically stable for  month after treatment for the patient to be eligible

Patients with  or fewer brain metastases that are less than  cm in diameter and asymptomatic are eligible; lesions that have been treated with stereotactic radiosurgery must be clinically stable for  month after treatment for the patient to be eligible; patients with surgically resectable brain metastases are eligible

Patients with  or fewer brain metastases that are less than  cm in diameter and asymptomatic are eligible; lesions that have been treated with stereotactic radiosurgery must be clinically stable for  month after treatment for the patient to be eligible; patients with surgically resected brain metastases are eligible

Patients with  or fewer brain metastases that are less than  cm in diameter and asymptomatic are eligible; lesions that have been treated with stereotactic radiosurgery must be clinically stable for  month after treatment for the patient to be eligible

Patients with  or less brain metastases that are less than  cm in diameter and asymptomatic are eligible; lesions that have been treated with stereotactic radiosurgery must be clinically stable for  month after treatment for the patient to be eligible; patients with surgically resected brain metastases are eligible

Patients with  or fewer brain metastases that are less than  cm in diameter and asymptomatic are eligible; lesions that have been treated with stereotactic radiosurgery must be clinically stable for  month after treatment for the patient to be eligible; patients with surgically resected brain metastases are eligible

Patients with  or fewer brain metastases that are less than  cm in diameter and asymptomatic are eligible; lesions that have been treated with stereotactic radiosurgery must be clinically stable for  month after treatment for the patient to be eligible